M&A - SHINECO, INC.

Form Type: 8-K/A

Filing Date: 2025-05-15

Corporate Action: Acquisition

Type: Update

Accession Number: 000164117225010437

Filing Summary: On May 12, 2025, Shineco Life Science Group Hong Kong Co., Limited, a subsidiary of Shineco, Inc., completed an acquisition of 75% of the equity interests in FuWang (HK) International Company Limited, following a stock purchase agreement with Yi Yang, the sole shareholder of FuWang (HK). The report amends a previous Form 8-K originally filed on May 13, 2025, to include financial statements that were previously excluded. The acquisition was finalized after all closing conditions were satisfied or waived. The financial statements of FuWang (HK) have been filed as exhibits to this amendment and include audited statements for fiscal years ended June 30, 2024 and 2023, as well as unaudited statements for the period ended December 31, 2024. Additionally, unaudited pro forma financial information is also included in the filing.

Form Type: 8-K

Filing Date: 2025-05-13

Corporate Action: Acquisition

Type: New

Accession Number: 000164117225009945

Filing Summary: On May 12, 2025, Shineco Life Science Group Hong Kong Co., Limited, a subsidiary of Shineco, Inc., completed the acquisition of 75% of the equity interests in FuWang (HK) International Company Limited in exchange for RMB 63.89 million (approximately US$8.9 million) in cash, 3,400,000 shares of common stock, and 71.42% equity interests in Dream Partner Limited. The transaction was executed following the fulfillment of closing conditions as stipulated in the stock purchase agreement dated March 20, 2025, with Yi Yang, the sole shareholder of FuWang (HK). The shares were issued in reliance on Rule 902 of Regulation S, confirming that the seller was not a U.S. person and did not acquire shares for the benefit of any U.S. person. The form includes details regarding the financial statements and pro forma financial information to be filed in subsequent amendments.

Form Type: 8-K

Filing Date: 2025-04-23

Corporate Action: Acquisition

Type: New

Accession Number: 000164117225005783

Filing Summary: On April 22, 2025, Shineco Life Science Group Hong Kong Co., Limited (a subsidiary of Shineco, Inc.) entered into a share purchase agreement with Dr. Lim Kah Meng, the sole shareholder of InfiniClone Limited, to acquire 51% of InfiniClone's equity interests. The transaction includes a cash payment of US$19,895,600 and the issuance of 3,450,000 shares of Shineco, Inc.'s common stock to the seller. The transaction has been approved by the board of directors and is to be completed within 90 days. As of the report date, the cash has not yet been paid, and the shares have not been transferred, pending compliance with the agreement's terms.

Form Type: 8-K

Filing Date: 2025-03-20

Corporate Action: Acquisition

Type: New

Accession Number: 000149315225011015

Filing Summary: On March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited, a subsidiary of Shineco, Inc., entered into a stock purchase agreement with Yi Yang, selling 75% equity interest in FuWang (HK) International Company Limited. The transaction includes a cash payment of RMB 63.89 million, issuance of 3,400,000 shares of common stock, and transfer of 71.42% equity interest in Dream Partner Limited. The deal has been approved by the board of directors. The cash payment and stock transfers have not occurred as of the report date. Several conditions and timelines for the transaction are outlined in the agreement, which is filed as an exhibit.